开发和描述创新的尼富尔蒂莫克斯配方作为治疗查加斯病的替代疗法
Ana Lia Mazzeti1, Karolina Ribeiro Gonçalves2, Patrícia Ferreira Boasquivis3
1Laboratório Integrado de Imunoparasitologia e Farmacotoxicologia, Universidade do Estado de Minas Gerais, Unidade Acadêmica de Passos, Passos 37900-106, MG, Brazil.
Tropical medicine and infectious disease
|February 25, 2025
概括
对查加斯病的新药物输送系统,在自我乳化系统和植入物中使用nifurtimox (NFX),显示出治疗这种被忽视的热带疾病的前景,特别是在慢性感染中.
科学领域:
- 制药科学 制药科学
- 热带医学 热带医学
- 药物输送系统 药物输送系统
背景情况:
- 查加斯病是由*Trypanosoma cruzi*引起的,是一种被忽视的热带疾病,治疗选择不足.
- 目前使用nifurtimox (NFX) 治疗的疗效有变化,特别是在慢性感染中,并导致副作用限制治疗坚持.
- 需要改进治疗策略,以提高疗效和患者的遵从性.
研究的目的:
- 开发和描述尼福蒂莫克斯 (NFX) 的新型药物输送系统,以改善查加斯病的治疗.
- 评估基于脂质的自我乳化药物输送系统 (SEDDS) 和含有NFX的多烯酸植入物的疗效和安全性.
- 评估这些配方作为治疗T. cruzi感染的替代方案的潜力,特别是在慢性阶段.
主要方法:
- 开发和表征NFX装载的SEDDS和聚烯酸植入物.
- 在体外评估NFX-SEDDS的抗*T. cruzi*活性和细胞毒性.
- 在T. cruzi*感染的小鼠体内研究以评估寄生虫抑制和治愈率.
- 使用热分析,X射线衍射和显微镜在植入物中的NFX-聚合物相互作用的表征.
主要成果:
- SEDDS配方改变了NFX释放动力学,而植入物显示了最小的NFX-聚合物相互作用.
- 在实验室中,NFX-SEDDS表现出增强的抗*T. cruzi*活性,哺乳动物细胞毒性低.
- 无论是NFX-SEDDS还是植入物,都有效地减少了感染小鼠的寄生病,实现了与口服NFX.EDDS相比的治愈率.
- NFX植入物提供了持续的疗效和改善的耐受性,相当于40剂口服剂量.
结论:
- 创新的NFX装载的SEDDS和植入物在治疗T. cruzi*感染中有效.
- 这些新型配方为查加斯病管理提供了一个有前途的替代方案,可能会提高坚持和有效性,特别是在慢性病例中.
- 开发的药物输送系统代表了解决被忽视的热带疾病 (如查加斯病) 治疗的未满足需求的重大进步.
相关概念视频
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
American Trypanosomiasis
Chagas disease, or American trypanosomiasis, is a vector-borne parasitic infection caused by Trypanosoma cruzi, a flagellated protozoan (kinetoplastid) of the family Trypanosomatidae. The disease is endemic in Latin America, although cases are increasingly reported worldwide due to human migration. Transmission most commonly occurs when feces of infected triatomine bugs contaminate bite wounds or mucosal surfaces; additional routes include congenital, transfusional, transplant-related, and oral...
Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...


